Abstract:Background: Exenatide is an insulinotropic peptide drug for type 2 diabetes treatment with low risk of hypoglycemia, and is administrated by subcutaneous injection. Oral administration is the most preferred route for lifelong treatment of diabetes, but oral delivery of peptide drug remains a significant challenge due to the absorption obstacles in gastrointestinal tract. We aimed to produce exenatide-loaded nanoparticles containing absorption enhancer, protectant and stabilizer using FDA approved inactive ingredients and easy to scale-up method, and to evaluate their long-term oral therapeutic effect in type 2 diabetes db/db mice. Results: Two types of nanoparticles, named COM NPs and DIS NPs, were fabricated using anti-solvent precipitation method. In COM NPs, the exenatide was complexed with cholic acid and phosphatidylcholine to increase the exenatide loading efficiency. In both nanoparticles, zein acted as the cement and the other ingredients were embedded in zein nanoparticles by hydrophobic interaction. Casein acted as the stabilizer. The nanoparticles had excellent lyophilization, storage and re-dispersion stability. Hypromellose phthalate protected the loaded exenatide from degradation in simulated gastric fluid. Cholic acid promoted the intestinal absorption of the loaded exenatide via bile acid transporters. The exenatide loading efficiencies of COM NPs and DIS NPs were 79.7% and 53.6%, respectively. The exenatide oral pharmacological availability of COM NPs was 18.6% and DIS NPs was 13.1%. COM NPs controlled the blood glucose level of the db/db mice well and the HbA1c concentration significantly decreased to 6.8% during and after 7 weeks of once daily oral administration consecutively. Both DIS NPs and COM NPs oral groups substantially increased the insulin secretion by more than 60% and promoted the β-cell proliferation by more than 120% after the 7-week administration. Conclusions: Both COM NPs and DIS NPs are promising systems for oral delivery of exenatide, and COM NPs are better in blood glucose level control than DIS NPs. Using prolamin to produce multifunctional nanoparticles for oral delivery of peptide drug by hydrophobic interaction is a simple and effective strategy.

An Orally Available Hypoglycaemic Peptide Taken Up by Caveolae Transcytosis Displays Improved Hypoglycaemic Effects and Body Weight Control in Db/db Mice

An Oral GLP-1 and GIP Dual Receptor Agonist Improves Metabolic Disorders in High Fat-Fed Mice

C-terminal Site-Specific PEGylated Exendin-4 Analog: A Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Diabetic Db/db Mice.

A Novel Oral Glucagon-Like Peptide 1 Receptor Agonist Protects Against Diabetic Cardiomyopathy Via Alleviating Cardiac Lipotoxicity Induced Mitochondria Dysfunction

A Novel Peptide with Similar Pharmacology to Exenatide in Rodents As GLP-1 Receptor Agonist

Novel Glucagon- and OXM-based Peptides Acting Through Glucagon and GLP-1 Receptors with Body Weight Reduction and Anti-Diabetic Properties.

Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice

The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo

A Novel Selective VPAC2 Agonist Peptide-Conjugated Chitosan Modified Selenium Nanoparticles with Enhanced Anti-Type 2 Diabetes Synergy Effects

Biased agonists with less glucagon-like peptide-1 receptor-mediated endocytosis prolong hypoglycaemic effects

Emerging Technologies to Achieve Oral Delivery of GLP-1 and GLP-1 Analogs for Treatment of Type 2 Diabetes Mellitus (T2DM)

The Discovery and Characterization of a Potent DPP-IV Inhibitory Peptide from Oysters for the Treatment of Type 2 Diabetes Based on Computational and Experimental Studies

2-(3,4-Dihydro-2h-pyrrolium-1-yl)-3oxoindan-1-olate (DHPO), a Novel, Synthetic Small Molecule That Alleviates Insulin Resistance and Lipid Abnormalities.

Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.

Amelioration of Hypoglycemic Peptide MoHpP-2 from Moringa Oleifera Seeds in C2C12 / IR Cells and Type 2 Diabetes Mellitus Mice

Evolution of peptide YY analogs for the management of type 2 diabetes and obesity

Glucose-Responsive Nanochaperones Mediate Exendin-4 Delivery for Enhancing Therapeutic Effects

PGLP-1, a Novel Long-Acting Dual-Function GLP-1 Analog, Ameliorates Streptozotocin-Induced Hyperglycemia and Inhibits Body Weight Loss.

Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice

An orally administered glucose-responsive polymeric complex for high-efficiency and safe delivery of insulin in mice and pigs